

Date: January 10, 2018

To,	To,			
The Manager,	The Department of Corporate Service,			
Listing Department,	Bombay Stock Exchange Limited,			
National Stock Exchange of India Limited,	Phiroze Jeejeebhoy Tower,			
Exchange Plaza, C-1, Block-G, Bandra - Kurla Complex,	Dalal Street, Mumbai – 400 001.			
Bandra (E), Mumbai – 400 051.				
SYMBOL - LINCOLN	Scrip Code - 531633			

Dear Sir,

SUB: STATEMENT OF INVESTOR COMPLAINTS FOR THE QUARTER ENDED ON DECEMBER 31, 2017.

Details of Investor Complaints as required under Regulation 13 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 is as below:

SR. NO.	DETAILS OF INVESTOR COMPLAINTS	NUMBER OF COMPLAINTS 3 MONTHS ENDED ON 31-12-2017
1.	No. of Investor Complaints pending at the beginning of the Quarter	NIL
2.	No. of Investor Complaints received during the Quarter	NIL
3.	No. of Investor Complaints disposed of during the Quarter	NIL
4.	No. of Investor Complaints remaining unresolved at the end of the Quarter	NIL

Kindly acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,
FOR LINCOLN PHARMACEUTICALS LIMITED

MAHENDRA G. PATEL MANAGING DIRECTOR

DIN: 00104706

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India **Phone :** +91-79-6777 8000 | **Fax :** +91-79-6777 8062 | **CIN** L24230GJ1995PLC024288

E-mail: info@lincolnpharma.com | **Website:** www.lincolnpharma.com

Factory: 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721. Ta.: Kalol, Dist. Gandhinagar, (Guj.)

Phone: 02764-665000 | Fax: 02764-281809

E-mail: khatraj@lincolnpharma.com



